Screener
King Pharmaceuticals KG Cash Acquired From Acquisition
Cash Acquired From Acquisition at other companies
Other financials
Where this comes from
Reported directly by King Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashAcquiredFromAcquisition.
The source filing: King Pharmaceuticals’s 10-K, filed March 13, 2026.
- Filed
- Mar 13, 2026, 8:06 AM EDT
- Fiscal year
- FY2025
- Accession
- 0001628280-26-017506
| For the Year Ended December 31, | 2025 | 2024 |
|---|---|---|
| Proceeds from sales of fixed maturities | 62,788 | — |
| Proceeds from maturities, paydowns and calls of fixed maturities | 85,202 | — |
| Proceeds from sale and redemption of other investments | 2,954 | — |
| Cash acquired from purchase of business | 79,807 | — |
| Net loan receivable from related party | 22,433 | — |
| Others, net | (21) | — |
| Net cash provided by investing activities | 146,945 | — |
| Cash flows from financing activities: |
Item 8. Financial Statements and Supplementary Data.
FAQ
- What is King Pharmaceuticals's cash acquired from acquisition?
- King Pharmaceuticals (KG) reported cash acquired from acquisition of $19.95M in Q4 2025.
- What does cash acquired from acquisition mean?
- Cash Acquired From Acquisition as reported by Kestrel Group Ltd.
Ask your AI about King Pharmaceuticals's cash acquired from acquisition.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude